Clinical trial
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
NCT00346827 · Britannia Pharmaceuticals Ltd., Industry · Completed
Key facts
| NCT number | NCT00346827 |
|---|---|
| Title | Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods. |
| Lead sponsor | Britannia Pharmaceuticals Ltd., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Apomorphine Nasal Powder |
| Enrollment | 36 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jun 30, 2006 |
| Last update posted | Jul 10, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: